Background Image
Previous Page  154 / 182 Next Page
Information
Show Menu
Previous Page 154 / 182 Next Page
Page Background

153

http://www.DGS-PraxisLeitlinien.de

Nr.

Nachweis

1

Abernethy AP, Samsa GP, Matchar DB. A clinical decision and economic analysis model

of cancer pain management. Am J Manag Care 2003; 9: 651-664.

2

Abernethy AP, Wheeler JL, Fortner BV. A health economic model of breakthrough pain.

American Journal of Managed Care 2008; 14(5): S129-140.

3

Abstral: US prescribing information. Verfügbar online von URL:

http://www.accessdata

.

fda.gov/drugsatfda_docs/label/2011/022510s000lbl.pdf. [aufgerufen am: 31.10.2012].

4

ACTIQ (fentanyl citrate oral transmucosal lozenge): US prescribing information. Frazer

(PA): Cephalon Inc. [online]. Verfügbar online von URL:

http://www.actiq.com/pdf/ac-

tiq_package_insert_4_5_07.pdf [aufgerufen am: 31.10.2012].

5

American Pain Foundation. Breakthrough cancer pain: mending the break in the conti-

nuum of care. J Pain Palliat Care Pharmacother 2011; 25(3): 252-264.

6

Aronoff G, Brennan M, Pritchard D, Ginsberg B. Evidence-based oral transmucosal

fentanyl citrate (OTFC) dosing guidelines. Pain Med 2005; 6: 305-314.

7

Artikel 1, 2 Abs. 1 1 und 2, Grundgesetz der Bundesrepublik Deutschland.

8

Ashburn MA, Slevin KA, Messina J, Xie F. The efficacy and safety of fentanyl buccal tab-

let compared with immediate-release oxycodone for the management of breakthrough

pain in opioid-tolerant patients with chronic pain. Anesth Analg 2011; 112(3): 693-702.

9

Assessment Report for Instanyl. Verfügbar online über:

http://www.ema.europa.eu/

docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000959/

WC500033144.pdf. [aufgerufen am 31.10.2012].

10

Bailey F, Farley A. Oral opioid drugs. In: Davies A, editor. Cancer-related breakthrough

pain. Oxford: Oxford University Press; 2006, 43-55.

11

Baker L, Lee M, Regnard C, Crack L, Callin S. Evolving spinal analgesia practice in palliati-

ve care. Palliative medicine 2004; 18: 507-515.

12

Bennet M. The LANSS pain scale: the Leeds assessment of neuropathic symptoms and

signs. Pain 2001; 92: 147-157.

13

Bennett D, Burton AW, Fishman S, et al. Consensus panel recommendations for the

assessment and management of breakthrough pain. Part 2. Management. Pharm Ther

2005; 30: 354-361.

14

Bennett D. Consensus panel recommendations for the assessment and management of

breakthrough pain. Part 1 assessment. Pharmacy and Therapeutics 2005; 30: 296-301.

15

Bernstein C, Lateef B, Fine PG. Interventional pain management procedures in older

patients. In: Gibson S, Weiner D (Hrsg.), Pain in older persons. Seattle: IASP Press, 2005.

16

Bertram L, Stiehl S, Elsner F, Radbruch L, Davies A, Nauck F, Alt-Epping A. Erfahrungen

von Tumorpatienten mit Durchbruchschmerzen und medikamentösen Behandlungen.

Der Schmerz 2010; 24: 605-612.

17

Bilen A, Ali A, Baturay F, Altan A. Breakthrough pain frequency in cancer patients and

the efficiency of oral transmucosal fentanyl citrate. Agri 2010; 22(3): 103-108.

Literaturverzeichnis